People: Dean L. Fanelli, Ph.D., Partner

Photo of Dean L. Fanelli, Ph.D., Partner

Dean L. Fanelli, Ph.D.

Partner

Washington, D.C.
Direct: (202) 828-3573
0

Dean L. Fanelli, Ph.D. is a partner in the Intellectual Property group of the Litigation Department in Seyfarth Shaw LLP’s Washington D.C. office.  Dr. Fanelli focuses his practice on pharmaceutical patent litigation under the Hatch-Waxman Act with particular emphasis on developing Paragraph IV litigation strategies and biosimilar market assessment, patent identification, and litigation strategy.  Dr. Fanelli also has significant experience with the interplay between patent and FDA laws under the Hatch-Waxman Act.

Dr. Fanelli’s practice spans the chemical, pharmaceutical, and biotechnology industries, and his expertise lies in patent portfolio creation and management, counseling, technology transactions, due diligence, and opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions.  Dr. Fanelli’s experience with the pharmaceutical and chemical technologies includes work with new chemical entities, pharmaceutical formulations, polymers, diagnostics, and medical devices.  Dr. Fanelli also regularly handles IP issues attendant to mergers and acquisitions and financing for life sciences companies.

Previously, Dr. Fanelli was a Founding Partner and Chair of Fanelli Haag PLLC.  Fanelli Haag joined Seyfarth Shaw LLP in October 2016. Fanelli Haag was a leading intellectual property boutique law firm focused on issues facing the biotechnology, pharmaceutical, and chemical industries.  In 2015, Corporate Counsel ranked Fanelli Haag as a “Most-Favored IP Boutique — One of the Best Firms in IP,” according to a report from BTI Consulting Group.  CorporateINTL Magazine named Fanelli Haag “2016 Biotech Patent Law Firm of the Year” in Washington, D.C. Additionally, Fanelli Haag was named ACQ Global Legal Awards' 2016 “Game Changer of the Year” in Washington, D.C.

Dr. Fanelli has firsthand experience in translating technologies into a successful commercial ventures.  While at Fanelli Haag, Dr. Fanelli was a co-founder of PhosImmune, Inc., an immuno-oncology neoantigen discovery startup company co-founded and built by Dean Fanelli and Thomas Haag and ultimately acquired by Agenus, Inc. (NASDAQ: AGEN) in December 2015.  In addition, Dr. Fanelli has developed various patent portfolios for commercially relevant products including those directed to:  Dificid® (fidaxomicin), which is currently marketed for the treatment of infections related to C. difficile, and Nexterone® (amiodarone HCl), marketed for the treatment and prophylaxis of ventricular fibrillation. 

Prior to founding Fanelli Haag, Dr. Fanelli was in private practice in the Washington D.C. office of an international law firm, where his work focused primarily on patent prosecution and counseling of clients in the pharmaceutical, chemical, veterinary, consumer products, and nutritional industries.  Dr. Fanelli gained additional experience in strategic patent management and licensing while seconded in-house with an international pharmaceutical drug-delivery company and while at a major consumer product company.

Dr. Fanelli actively participates in the American Intellectual Property Law Association (AIPLA), American Bar Association and American Chemical Society.  He is also a member of AIPLA‘s Intellectual Property Practice in Japan Committee. Dr. Fanelli’s articles have been published in peer-reviewed scientific journals, and he has given presentations and published articles on various topics related to intellectual property.

Dean L. Fanelli, Ph.D. is a partner in the Intellectual Property group of the Litigation Department in Seyfarth Shaw LLP’s Washington D.C. office.  Dr. Fanelli focuses his practice on pharmaceutical patent litigation under the Hatch-Waxman Act with particular emphasis on developing Paragraph IV litigation strategies and biosimilar market assessment, patent identification, and litigation strategy.  Dr. Fanelli also has significant experience with the interplay between patent and FDA laws under the Hatch-Waxman Act.

Dr. Fanelli’s practice spans the chemical, pharmaceutical, and biotechnology industries, and his expertise lies in patent portfolio creation and management, counseling, technology transactions, due diligence, and opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions.  Dr. Fanelli’s experience with the pharmaceutical and chemical technologies includes work with new chemical entities, pharmaceutical formulations, polymers, diagnostics, and medical devices.  Dr. Fanelli also regularly handles IP issues attendant to mergers and acquisitions and financing for life sciences companies.

Previously, Dr. Fanelli was a Founding Partner and Chair of Fanelli Haag PLLC.  Fanelli Haag joined Seyfarth Shaw LLP in October 2016. Fanelli Haag was a leading intellectual property boutique law firm focused on issues facing the biotechnology, pharmaceutical, and chemical industries.  In 2015, Corporate Counsel ranked Fanelli Haag as a “Most-Favored IP Boutique — One of the Best Firms in IP,” according to a report from BTI Consulting Group.  CorporateINTL Magazine named Fanelli Haag “2016 Biotech Patent Law Firm of the Year” in Washington, D.C. Additionally, Fanelli Haag was named ACQ Global Legal Awards' 2016 “Game Changer of the Year” in Washington, D.C.

Dr. Fanelli has firsthand experience in translating technologies into a successful commercial ventures.  While at Fanelli Haag, Dr. Fanelli was a co-founder of PhosImmune, Inc., an immuno-oncology neoantigen discovery startup company co-founded and built by Dean Fanelli and Thomas Haag and ultimately acquired by Agenus, Inc. (NASDAQ: AGEN) in December 2015.  In addition, Dr. Fanelli has developed various patent portfolios for commercially relevant products including those directed to:  Dificid® (fidaxomicin), which is currently marketed for the treatment of infections related to C. difficile, and Nexterone® (amiodarone HCl), marketed for the treatment and prophylaxis of ventricular fibrillation. 

Prior to founding Fanelli Haag, Dr. Fanelli was in private practice in the Washington D.C. office of an international law firm, where his work focused primarily on patent prosecution and counseling of clients in the pharmaceutical, chemical, veterinary, consumer products, and nutritional industries.  Dr. Fanelli gained additional experience in strategic patent management and licensing while seconded in-house with an international pharmaceutical drug-delivery company and while at a major consumer product company.

Dr. Fanelli actively participates in the American Intellectual Property Law Association (AIPLA), American Bar Association and American Chemical Society.  He is also a member of AIPLA‘s Intellectual Property Practice in Japan Committee. Dr. Fanelli’s articles have been published in peer-reviewed scientific journals, and he has given presentations and published articles on various topics related to intellectual property.

Education

  • J.D., The George Washington University Law School

  • Ph.D., Organic Chemistry, Temple University

  • B.S., Chemistry, Villanova University

Admissions

  • District of Columbia
  • New York
  • Registered Patent Attorney, United States Patent and Trademark Office

Courts

  • United States Supreme Court

Affiliations

  • American Chemical Society
  • American Bar Association
  • American Intellectual Property Law Association
  • District of Columbia Bar Association
  • New York State Bar Association

Presentations

  • “The Promises and Perils of Blockchain as Content Distribution Technology.” Webinar Presented by the Knowledge Group (November 13, 2018)
  • “Chemical & Life Sciences Patents: A Look Back and A Sneak Peek to the Future,” Webinar Presented by the Knowledge Group (October 11, 2018)
  • “Patent Race on the Emergence of Cryptocurrencies and Blockchain Technology,” Webinar Presented by the Knowledge Group (August 23, 2018)
  • “Bridging the Gap Between EU and U.S. Biotech Inventions Protection,” Webinar Presented by the Knowledge Group (April 17, 2018)
  •  “Biosimilar Litigation and Your BPCIA Compliance: Key Strategies In Light of AbbVie v. Boehringer,” Webinar Presented by the Knowledge Group (March 22, 2018)
  •  “Understanding the BPCIA Litigation Pathway Amidst the Increasing Biosimilar Disputes,” Webinar Presented by the Knowledge Group (November 6, 2017)
  • “Trends in Paragraph IV Challenges: What Lies Ahead in 2017 and Beyond,” Webinar Presented by the Knowledge Group (May 24, 2017)
  • "Protecting Your Trade Secrets in the Pharmaceutical Industry," Webinar, presented by Seyfarth Shaw LLP (June 28, 2017)
  • “Tips and Strategies in Winning Paragraph IV Disputes in 2016 & Beyond,” Webinar Presented by the Knowledge Group (August 23, 2016)
  • “Patent Protection for Pharma and Biotechnology in 2016,” Webinar Presented by the Knowledge Group (April 18, 2016)
  • 7th Global Intellectual Property Convention 2015, New Delhi India (January 2015)
  • 6th Global Intellectual Property Convention 2014, New Delhi India (January 2014)
  • World Intellectual Property Forum 2013, Bangalore, India (January 2013)

Publications

Legal Publications

  • Co-Author, “Teva Sues FDA Alleging Unlawful Interpretation of the Definition of First Applicant,” BioLoquitur Life Sciences Blog (October 24, 2018)
  • Co-Author, Tribal Immunity Cannot Be Asserted to Escape IPR Proceedings,” BioLoquitur Life Sciences Blog (July 25, 2018)
  • Co-Author, “Seyfarth Shaw’s BioLoquitur Bulletin: Drugs Available in 2018 for Generic Competition,” BioLoquitur Life Sciences Blog (April 5, 2018)
  • “FDA’s Office of Generic Drugs: 2017 Annual Report Highlights,” BioLoquitur Life Sciences Blog (March 9, 2018)
  • Co-Author, “Seyfarth Shaw’s Hatch-Waxman and Biosimilars Litigation: 2017 Year-in-Review.” BioLoquitur Life Sciences Blog (February 8, 2018)
  • “Is Medical Marijuana Really Medicinal?” BioLoquitur Life Sciences Blog (November 8, 2017)
  • “FDA Provides New Product Specific Guidance for Development of Certain Generic Drug Products,” BioLoquitur Life Sciences Blog (November 6, 2017)
  • “Regeneron v. Merus: Federal Circuit Upholds Adverse Inference of Specific Intent to Deceive the USPTO,” BioLoquitur Life Sciences Blog (July 31, 2017)
  • Co-Author, "ANDA Filers Subject to Specific Personal Jurisdiction Based on Future Infliction of Real-World Market Injury," BioLoquitur Life Sciences Blog (April 5, 2016)
  • Co-Author, "Federal Circuit Affirms Holding of Obviousness of Claims Covering Warner Chilcott’s Osteoporosis Drug, Altevia®,”  BioLoquitur Life Sciences Blog (March 29, 2016)
  • Author, "Federal Circuit Determines that Certain PTO Delays May Not Necessitate Patent Term Adjustment,” BioLoquitur Life Sciences Blog (March 1, 2016)
  • Author, "Federal Circuit Confirms Same Inter Partes Review Panel Can Grant Petition and Make Final Determination,” BioLoquitur Life Sciences Blog (January 27, 2016)
  • Co-Author, "Federal Circuit Finds Inter Partes Reviews Constitutional," BioLoquitur Life Sciences Blog (December 8, 2015)
  • Co-Author, "PTO Reports to Congress on Confirmatory Genetic Diagnostic Testing," BioLoquitur Life Sciences Blog, (October 26, 2015)
  • Co-Author, "Reputational Harm for Failing to Name an Inventor on a Patent Could Give Rise to Article III Standing,”  BioLoquitur Life Sciences Blog, (October 19, 2015)
  • Co Author, "Patent Licensors Beware – No Challenge Clause Does Not Bar Challenge Before the PTAB," BioLoquitur Life Sciences Blog (September 28, 2015)
  • Co-Author, "Amgen v. Sandoz: What "Shall" Biosimilar Applicants Do?,"" BioLoquitur Life Sciences Blog (August 24, 2015)
  • Co-Author, "Federal Circuit Deals Blow to Biotech Industry and Diagnostic Method Patents," BioLoquitur Life Sciences Blog (June 15, 2015)
  • Co-Author, “Reverse Settlement Payments in Patent Disputes Come Under Scrutiny Under Both Federal Law and State Antitrust Law,” BioLoquitur Life Sciences Blog (June 1, 2015)
  • Co-Author, “The Future of Biosimilars in Health Care and Litigation,” Law360 (June 24, 2010)
  •  Co-Author, “Time is Money:  Federal Circuit Affirms Wyeth,” IPO Articles and Reports, Pats. Sec., 2010, No. 8
  • Co-Author, “The Future of Biosimilars in Health Care and Litigation,” Law 360 (June 28, 2010)
  • Co-Author, “A Review of Recent Decisions of the United States Court of Appeals for the Federal Circuit, 2007 Patent Law Decisions of the Federal Circuit,” Volume 57, No. 4, pp. 821-1038 (April 2008)
  • Author, “Claiming Novel Polymorphic Forms of Drug Products,” Journal of the Patent and Trademark Office Society, Volume 88, No. 12, pp. 1053-1067 (December 2006)

Scientific Publications

  • Co-Author, “Applications of the Sulfinimine-Mediated Asymmetric Strecker Synthesis to the Synthesis of α-Alkyl α-Amino Acids,” The Journal of Organic Chemistry (2000)
  • Co-Author, Sulfinimines (Thiooxime S-Oxides): Asymmetric Synthesis of (R)-(+)-β-Phenylalanine From (S)-(+)-N-(Benzylidene)-p-Toluenesulfinamide,” Organic Synthesis (2000)
  • Co-Author, “Asymmetric Synthesis of Sulfinimines (Thiooxime S-Oxides) From p-Toluenesulfinamide and Aldehydes and Ketones,” The Journal of Organic Chemistry (1999)
  • Co-Author, “Sulfinimine Medicated Asymmetric Synthesis of (R)-(4-Methoxy-3,5- dihydroxyphenyl) glycine: The Central Amino Acid of Vancomycin and Related Agents,” The Journal of Organic Chemistry (1998)
  • Co-Author, “Asymmetric Synthesis and Properties of Sulfinimines (Thiooxime S-Oxides),” The Journal of Organic Chemistry (1997)

Accolades

  • Recognized as a Legal 500 Recommended Attorney, 2017-2018
  • ACQ5 Law Awards 2017 “Biotech Patents Law Firm of the Year” in Washington, D.C.
  • ACQ5 Law Awards 2017 “Life Sciences Law Firm of the Year” in Washington, D.C.
  • ACQ Global Awards 2016 “Game Changer of the Year” in Washington, D.C.
  • ACQ Global Awards 2016 “Life Sciences Law Firm of the Year” in Washington, D.C.
  • Who's Who Adviser Handbook 2016, CorporateINTL
  • Winner CorporateINTL Magazine – 2016 Biotech Patent Law Firm of the Year in Washington, D.C.
  • Honor Roll for "Most-Favored Boutique -- one of the best firms in IP” in BTI Counseling Group’s 2015 Intellectual Property Outlook: Changes, Trends and Opportunities in IP & IP Litigation
  • International Law Office (ILO) “International Client Choice Award 2013” in the Category of “Intellectual Property Healthcare & Life Sciences” for excellence in client service
  • Temple University Dissertation Fellowship 1999
  • Temple University Case Fellow 1998
  • Temple University Swern Fellow 1998
  • Villanova Research Fellowship 1993
  • Rohm and Haas Research Fellowship 1992
  • Bryn Mawr College Summer Fellowship 1988